Exosome‐mediated PROTACs delivery to target viral infections

Abstract

Exosome‐based targeted delivery of Proteolysis‐Targeting Chimeras (PROTACs) is an innovative approach that provides a promising solution for addressing the complex issues of viral diseases. This strategy significantly mitigates the off‐target effects associated with traditional therapeutics by facilitating targeted delivery of PROTACs, which in turn enhances the overall therapeutic outcomes. Challenges like poor pharmacokinetics and unintended side effects, commonly observed with conventional PROTACs usage, are effectively managed with this approach. Emerging evidence affirms the potential of this delivery mechanism in curbing viral replication. However, it is crucial to undertake more comprehensive investigations for optimizing exosome‐based delivery systems and conducting stringent safety and efficacy assessments within preclinical and clinical settings. The advancements in this field could potentially redefine the therapeutic landscape for viral diseases, opening new vistas for their management and treatment.

Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy

“…Their potential to target previously "undruggable" proteins represents an innovative approach that expands the horizon of therapeutic options. 10,11 This review aspires to provide an all-encompassing examination of the current frontiers of cancer therapy. From the historical roots to the latest breakthroughs, including the novel and promising field of PROTACs, we embark on a detailed exploration that navigates the complex interplay among scientific innovation, clinical application, and ethical considerations.…”

“…By manipulation of the ubiquitin–proteasome system to induce targeted protein degradation, PROTACs have ushered in a new wave of possibilities in drug discovery and cancer treatment. Their potential to target previously “undruggable” proteins represents an innovative approach that expands the horizon of therapeutic options. , …”

Synergizing Proteolysis-Targeting Chimeras and Nanoscale Exosome-Based Delivery Mechanisms for HIV and Antiviral Therapeutics

“…This ligand forms the other end of the PROTAC molecule and recruits the E3 ligase. 22 Connecting these two ligands is a linker, the design of which is critical to the functionality of the PROTAC. The linker must be of optimal length and flexibility to allow for the formation of a ternary complex between the PROTAC, the target protein, and the E3 ligase.…”

“…The choice of E3 ligase is guided by various factors, including its expression across different tissues, its endogenous substrates, and the availability of a small molecule ligand for it. This ligand forms the other end of the PROTAC molecule and recruits the E3 ligase . Connecting these two ligands is a linker, the design of which is critical to the functionality of the PROTAC.…”

Revolutionizing Human papillomavirus (HPV)‐related cancer therapies: Unveiling the promise of Proteolysis Targeting Chimeras (PROTACs) and Proteolysis Targeting Antibodies (PROTABs) in cancer nano‐vaccines

“…Nano‐vaccines, leveraging the precision and immune‐stimulating properties of nanotechnology, offer enhanced antigen delivery and improved therapeutic outcomes 4 . Moreover, the integration of PROTACs and PROTABs into nano‐vaccines introduces a new dimension in the battle against cancer and viral diseases 5,6 . PROTACs, a novel class of drugs, demonstrate a unique capability to selectively degrade target proteins within cells 7,8 …”